Our clinical evidence

At KOUAGA, we don't ask you to take our word for it: we measure. Here are our two clinical studies and their results.

Prevention

Clinical study

Results expected early 2027
Objectif
To assess the effect of the prevention cream on the skin's elasticity, hydration and barrier function.
Volontaires
Around thirty volunteers
Durée
56 days - dermatological follow-up

Mesures instrumentales

  • Skin elasticityCutometer®
  • HydrationCorneometer®
  • Barrier functionTewameter®

Résultats

Detailed results will be published here as soon as they are available, with figures and methodology.
Fading

Clinical study

Results expected early 2027
Objectif
To assess changes in the appearance of recent stretch marks: relief and colour.
Volontaires
Around thirty volunteers
Durée
4 months - dermatological follow-up

Mesures instrumentales

  • Stretch mark reliefAntera 3D® 3D imaging
  • ColourAntera 3D® 3D imaging
  • Barrier functionTewameter®

Résultats

Detailed results will be published here as soon as they are available, with figures and methodology.

Why run clinical studies?

Stretch marks affect the vast majority of us, yet they remain little studied. Nothing requires us to go this far for a cosmetic product. We nevertheless chose to evaluate our two creams with the same methodological rigour as research, because an expert brand must prove what it claims.

A rigorous method

  • Studies conducted with a specialised clinical evaluation laboratory.
  • Measuring instruments recognised in dermatological evaluation, rather than individual participants' impressions.
  • Regular dermatological follow-up.
  • Predefined evaluation criteria.
  • An established statistical plan.

What is already established

The tolerance of both our products has been validated by toxicological assessment for all populations, including during pregnancy, breastfeeding and adolescence.

To understand what science knows today about stretch marks, and what it does not yet know, discover our page Stretch marks: the complete guide.